Earnings Call · Q3 FY2024·2024-10-31

Q3 24EPS -100.00%*·Rev n/aQ2 24EPS -4.97%·Rev n/aQ1 24EPS +13.69%·Rev n/aQ4 23EPS -4.88%·Rev n/a⚠ consensus missing

AGIOS PHARMACEUTICALS, INC. AGIO

Chris Taylor — Vice President, Investor Relations and Corporate Communications

Brian Goff — Chief Executive Officer

Sarah Gheuens — Senior Executive, Clinical Development

Tsveta Milanova — Senior Executive, Commercial/Launch

Cecilia Jones — Senior Executive, Finance

−4.0%1d on move date−2.1% vs SPY3d−3.2%5d+11.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AGIO calls or request research access.

More AGIO calls Browse calls Request research access